Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02967692




Registration number
NCT02967692
Ethics application status
Date submitted
16/11/2016
Date registered
18/11/2016

Titles & IDs
Public title
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Scientific title
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Secondary ID [1] 0 0
2016-002794-35
Secondary ID [2] 0 0
CPDR001F2301
Universal Trial Number (UTN)
Trial acronym
COMBI-i
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Spartalizumab
Other interventions - Placebo
Treatment: Drugs - Dabrafenib
Treatment: Drugs - Trametinib

Experimental: Part 1: Safety run-in Cohort - In Part 1, participants are treated at different dose levels to determine the recommended Phase 3 regimen of spartalizumab in combination with dabrafenib and trametinib. The starting dose of spartalizumab is 400 mg Q4W in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD).

Experimental: Part 2: Biomarker cohort - In Part 2, participants are treated with spartalizumab 400 mg Q4W in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD).

Experimental: Part 3- Arm 1: Spartalizumab in combination with dabrafenib and trametinib - In Part 3, participants are randomized to receive spartalizumab at the RP3R identified in Part 1 (400 mg Q4W) in combination with approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD)

Placebo comparator: Part 3- Arm 2: Placebo in combination with dabrafenib and trametinib - In Part 3, participants are randomized to receive matching placebo in combination with the approved dose of dabrafenib (150 mg BID) and trametinib (2 mg QD)


Treatment: Other: Spartalizumab
Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks

Other interventions: Placebo
Placebo is administered via intravenous infusion over 30 minutes once every 4 weeks

Treatment: Drugs: Dabrafenib
Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.

Treatment: Drugs: Trametinib
Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Other interventions
Intervention code [3] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety Run-In (Part 1): Number of Participants With Dose Limiting Toxicities (DLTs)
Timepoint [1] 0 0
Up to 8 weeks (Part 1)
Primary outcome [2] 0 0
Biomarker Cohort (Part 2): Change From Baseline in Programmed Cell Death-ligand 1 (PD-L1) Expression Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib
Timepoint [2] 0 0
Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
Primary outcome [3] 0 0
Biomarker Cohort (Part 2): Change From Baseline in CD8+ Cells Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib
Timepoint [3] 0 0
Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
Primary outcome [4] 0 0
Randomized (Part 3): Progression-Free Survival (PFS) as Per Investigator's Assessment by RECIST 1.1
Timepoint [4] 0 0
Up to disease progression or death due to any cause, whichever occurs first, assessed up to 2.8 years (Part 3)
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to death due to any cause, assessed up to approximately 5 years
Secondary outcome [2] 0 0
Overall Response Rate (ORR) as Per Investigator's Assessment by RECIST 1.1
Timepoint [2] 0 0
Part 1: Up to 3.3 years. Part 2: Up to 3 years. Part 3: Up to 2.8 years
Secondary outcome [3] 0 0
Duration of Response (DOR) as Per Investigator's Assessment by RECIST 1.1
Timepoint [3] 0 0
From first documented response to date of first documented progression or death, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3)
Secondary outcome [4] 0 0
Disease Control Rate (DCR) as Per Investigator's Assessment by RECIST 1.1
Timepoint [4] 0 0
Part 1: Up to 3.3 years. Part 2: Up to 3 years. Part 3: Up to 2.8 year
Secondary outcome [5] 0 0
Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Global Health Status Scores
Timepoint [5] 0 0
From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Secondary outcome [6] 0 0
Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Physical Functioning Scale Scores
Timepoint [6] 0 0
From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Secondary outcome [7] 0 0
Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Pain Symptom Scale Scores
Timepoint [7] 0 0
From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Secondary outcome [8] 0 0
Randomized (Part 3): Time to 10 Point Definitive Deterioration in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Global Health Status
Timepoint [8] 0 0
From baseline to date of at least 10 points relative to baseline worsening of the global health status score or death due to any cause, up to 2.8 years (Part 3)
Secondary outcome [9] 0 0
Randomized (Part 3): Change From Baseline in Function Assessment Cancer Therapy-melanoma (FACT-M) Melanoma Subscale Score
Timepoint [9] 0 0
From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Secondary outcome [10] 0 0
Randomized (Part 3): Change From Baseline in EuroQoL 5-level Instrument (EQ-5D-5L)- Visual Analog Scale (VAS) Score
Timepoint [10] 0 0
From baseline to 60 days post progression, assessed up to 2.8 years (Part 3)
Secondary outcome [11] 0 0
Randomized (Part 3): PFS as Per Investigator's Assessment by RECIST 1.1 by PD-L1 Expression
Timepoint [11] 0 0
Up to disease progression or death due to any cause, up to 2.8 years (Part 3)
Secondary outcome [12] 0 0
Randomized (Part 3): OS by PD-L1 Expression
Timepoint [12] 0 0
Up to death due to any cause, up to 5 years
Secondary outcome [13] 0 0
Spartalizumab Anti-drug Antibody (ADA) Prevalence at Baseline
Timepoint [13] 0 0
Baseline
Secondary outcome [14] 0 0
Spartalizumab ADA Incidence
Timepoint [14] 0 0
Throughout study until 150 days after the last dose of spartalizumab, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3).
Secondary outcome [15] 0 0
Trough Concentration (Ctrough) for Spartalizumab
Timepoint [15] 0 0
Pre-infusion on Day 1 of each Cycle starting from Cycle 2, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days
Secondary outcome [16] 0 0
Pre-dose Plasma Concentration for Dabrafenib
Timepoint [16] 0 0
Pre-infusion on Day 1 of every cycle from Cycle 2 to 12, and then every 6 cycles from Cycle 18 to 36, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days
Secondary outcome [17] 0 0
Pre-dose Plasma Concentration for Trametinib
Timepoint [17] 0 0
Pre-infusion on Day 1 of every cycle from Cycle 2 to 12, and then every 6 cycles from Cycle 18 to 36, up to 3.3 years (Part 1), 3 years (Part 2) and 2.8 years (Part 3). Cycle=28 days
Secondary outcome [18] 0 0
Number of Participants With Dose Interruptions
Timepoint [18] 0 0
From baseline to end of treatment, up to 5 years
Secondary outcome [19] 0 0
Number of Participants With Dose Reductions
Timepoint [19] 0 0
From baseline to end of treatment, up to 5 years
Secondary outcome [20] 0 0
Relative Dose Intensity
Timepoint [20] 0 0
From baseline to end of treatment, up to 5 years

Eligibility
Key inclusion criteria
Inclusion criteria Part 1: Safety run-in

* Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation
* Aspartate transaminase (AST) < 2.5× ULN and Alanine transaminase (ALT) < 2.5× ULN
* Measurable disease according to RECIST 1.1
* ECOG performance status = 1

Part 2: Biomarker cohort

* Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation
* At least two cutaneous or subcutaneous or nodal lesions for tumor sample collection
* Measurable disease according to RECIST 1.1
* ECOG performance status = 2

Part 3: Double-blind, randomized, placebo-controlled part

* Histologically confirmed, unresectable or metastatic melanoma with BRAF V600 mutation
* ECOG performance status = 2
* Measurable disease according to RECIST 1.1
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Part 1: Safety run-in

* Subjects with uveal or mucosal melanoma
* Any history of CNS metastases
* Prior systemic anti-cancer treatment for unresectable or metastatic melanoma
* Neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months prior to enrollmen
* Radiation therapy within 4 weeks prior to start of study treatment
* Active autoimmune disease, and/or history of autoimmune disease(s) that required treatment

Parts 2 & 3: Biomarker cohort & double-blind, randomized, placebo-controlled part

* Subjects with uveal or mucosal melanoma
* Prior systemic anti-cancer treatment for unresectable or metastatic melanoma
* Neoadjuvant and/or adjuvant therapy for melanoma completed less than 6 months prior to enrollment
* Radiation therapy within 4 weeks prior to start of study treatment
* Clinically active cerebral melanoma metastasis.
* Active autoimmune disease, and/or history of autoimmune disease(s) that required treatment

Other protocol-defined Inclusion/Exclusion may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/02/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
21/08/2024
Sample size
Target
Accrual to date
Final
573
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Novartis Investigative Site - Gateshead
Recruitment hospital [2] 0 0
Novartis Investigative Site - North Sydney
Recruitment hospital [3] 0 0
Novartis Investigative Site - Greenslopes
Recruitment hospital [4] 0 0
Novartis Investigative Site - Melbourne
Recruitment hospital [5] 0 0
Novartis Investigative Site - Nedlands
Recruitment postcode(s) [1] 0 0
2290 - Gateshead
Recruitment postcode(s) [2] 0 0
2060 - North Sydney
Recruitment postcode(s) [3] 0 0
4120 - Greenslopes
Recruitment postcode(s) [4] 0 0
3004 - Melbourne
Recruitment postcode(s) [5] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Kansas
Country [3] 0 0
United States of America
State/province [3] 0 0
Maryland
Country [4] 0 0
United States of America
State/province [4] 0 0
Nebraska
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Pennsylvania
Country [7] 0 0
United States of America
State/province [7] 0 0
Tennessee
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
United States of America
State/province [9] 0 0
Utah
Country [10] 0 0
Argentina
State/province [10] 0 0
Buenos Aires
Country [11] 0 0
Argentina
State/province [11] 0 0
Santa Fe
Country [12] 0 0
Austria
State/province [12] 0 0
Tyrol
Country [13] 0 0
Austria
State/province [13] 0 0
Graz
Country [14] 0 0
Austria
State/province [14] 0 0
Linz
Country [15] 0 0
Austria
State/province [15] 0 0
Salzburg
Country [16] 0 0
Austria
State/province [16] 0 0
St Poelten
Country [17] 0 0
Belgium
State/province [17] 0 0
Brussel
Country [18] 0 0
Belgium
State/province [18] 0 0
Bruxelles
Country [19] 0 0
Brazil
State/province [19] 0 0
PR
Country [20] 0 0
Brazil
State/province [20] 0 0
RS
Country [21] 0 0
Brazil
State/province [21] 0 0
SP
Country [22] 0 0
Brazil
State/province [22] 0 0
Rio de Janeiro
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Plovdiv
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Sofia
Country [25] 0 0
Canada
State/province [25] 0 0
British Columbia
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
Chile
State/province [28] 0 0
Araucania
Country [29] 0 0
Chile
State/province [29] 0 0
Santiago
Country [30] 0 0
Czechia
State/province [30] 0 0
Czech Republic
Country [31] 0 0
Czechia
State/province [31] 0 0
CZE
Country [32] 0 0
Czechia
State/province [32] 0 0
Poruba
Country [33] 0 0
Czechia
State/province [33] 0 0
Praha 10
Country [34] 0 0
Czechia
State/province [34] 0 0
Praha
Country [35] 0 0
Denmark
State/province [35] 0 0
Aarhus N
Country [36] 0 0
France
State/province [36] 0 0
Haute Vienne
Country [37] 0 0
France
State/province [37] 0 0
Amiens
Country [38] 0 0
France
State/province [38] 0 0
Besancon Cedex
Country [39] 0 0
France
State/province [39] 0 0
Bobigny Cedex
Country [40] 0 0
France
State/province [40] 0 0
Bordeaux Cedex
Country [41] 0 0
France
State/province [41] 0 0
Boulogne Billancourt
Country [42] 0 0
France
State/province [42] 0 0
Caen
Country [43] 0 0
France
State/province [43] 0 0
Clermont Ferrand
Country [44] 0 0
France
State/province [44] 0 0
Dijon
Country [45] 0 0
France
State/province [45] 0 0
Grenoble
Country [46] 0 0
France
State/province [46] 0 0
Le Mans
Country [47] 0 0
France
State/province [47] 0 0
Lille
Country [48] 0 0
France
State/province [48] 0 0
Lorient
Country [49] 0 0
France
State/province [49] 0 0
Lyon
Country [50] 0 0
France
State/province [50] 0 0
Marseille
Country [51] 0 0
France
State/province [51] 0 0
Mulhouse cedex
Country [52] 0 0
France
State/province [52] 0 0
Nice
Country [53] 0 0
France
State/province [53] 0 0
Paris 10
Country [54] 0 0
France
State/province [54] 0 0
Pierre Benite
Country [55] 0 0
France
State/province [55] 0 0
Poitiers
Country [56] 0 0
France
State/province [56] 0 0
Reims
Country [57] 0 0
France
State/province [57] 0 0
Rouen
Country [58] 0 0
France
State/province [58] 0 0
Strasbourg Cedex
Country [59] 0 0
France
State/province [59] 0 0
Toulouse
Country [60] 0 0
France
State/province [60] 0 0
Vandoeuvre-les-Nancy
Country [61] 0 0
France
State/province [61] 0 0
Villejuif
Country [62] 0 0
Germany
State/province [62] 0 0
Baden Wuerttemberg
Country [63] 0 0
Germany
State/province [63] 0 0
Bavaria
Country [64] 0 0
Germany
State/province [64] 0 0
Berlin
Country [65] 0 0
Germany
State/province [65] 0 0
Bonn
Country [66] 0 0
Germany
State/province [66] 0 0
Chemnitz
Country [67] 0 0
Germany
State/province [67] 0 0
Dresden
Country [68] 0 0
Germany
State/province [68] 0 0
Duesseldorf
Country [69] 0 0
Germany
State/province [69] 0 0
Erfurt
Country [70] 0 0
Germany
State/province [70] 0 0
Essen
Country [71] 0 0
Germany
State/province [71] 0 0
Freiburg
Country [72] 0 0
Germany
State/province [72] 0 0
Gera
Country [73] 0 0
Germany
State/province [73] 0 0
Halle S
Country [74] 0 0
Germany
State/province [74] 0 0
Hamburg
Country [75] 0 0
Germany
State/province [75] 0 0
Hannover
Country [76] 0 0
Germany
State/province [76] 0 0
Heidelberg
Country [77] 0 0
Germany
State/province [77] 0 0
Homburg
Country [78] 0 0
Germany
State/province [78] 0 0
Kiel
Country [79] 0 0
Germany
State/province [79] 0 0
Leipzig
Country [80] 0 0
Germany
State/province [80] 0 0
Mainz
Country [81] 0 0
Germany
State/province [81] 0 0
Marburg
Country [82] 0 0
Germany
State/province [82] 0 0
Minden
Country [83] 0 0
Germany
State/province [83] 0 0
Muenchen
Country [84] 0 0
Germany
State/province [84] 0 0
Muenster
Country [85] 0 0
Germany
State/province [85] 0 0
Stade
Country [86] 0 0
Germany
State/province [86] 0 0
Tuebingen
Country [87] 0 0
Greece
State/province [87] 0 0
Athens
Country [88] 0 0
Hungary
State/province [88] 0 0
Budapest
Country [89] 0 0
Hungary
State/province [89] 0 0
Debrecen
Country [90] 0 0
Hungary
State/province [90] 0 0
Szeged
Country [91] 0 0
Israel
State/province [91] 0 0
Haifa
Country [92] 0 0
Israel
State/province [92] 0 0
Jerusalem
Country [93] 0 0
Israel
State/province [93] 0 0
Ramat Gan
Country [94] 0 0
Italy
State/province [94] 0 0
BA
Country [95] 0 0
Italy
State/province [95] 0 0
BG
Country [96] 0 0
Italy
State/province [96] 0 0
BO
Country [97] 0 0
Italy
State/province [97] 0 0
BS
Country [98] 0 0
Italy
State/province [98] 0 0
FC
Country [99] 0 0
Italy
State/province [99] 0 0
GE
Country [100] 0 0
Italy
State/province [100] 0 0
MB
Country [101] 0 0
Italy
State/province [101] 0 0
MI
Country [102] 0 0
Italy
State/province [102] 0 0
MO
Country [103] 0 0
Italy
State/province [103] 0 0
PD
Country [104] 0 0
Italy
State/province [104] 0 0
RM
Country [105] 0 0
Italy
State/province [105] 0 0
SI
Country [106] 0 0
Italy
State/province [106] 0 0
TO
Country [107] 0 0
Italy
State/province [107] 0 0
VR
Country [108] 0 0
Italy
State/province [108] 0 0
Napoli
Country [109] 0 0
Japan
State/province [109] 0 0
Fukuoka
Country [110] 0 0
Japan
State/province [110] 0 0
Kyoto
Country [111] 0 0
Japan
State/province [111] 0 0
Osaka
Country [112] 0 0
Japan
State/province [112] 0 0
Tokyo
Country [113] 0 0
Mexico
State/province [113] 0 0
Distrito Federal
Country [114] 0 0
Mexico
State/province [114] 0 0
Guanajuato
Country [115] 0 0
Mexico
State/province [115] 0 0
Jalisco
Country [116] 0 0
Netherlands
State/province [116] 0 0
Zuid Holland
Country [117] 0 0
Netherlands
State/province [117] 0 0
Amersfroort
Country [118] 0 0
Norway
State/province [118] 0 0
Oslo
Country [119] 0 0
Poland
State/province [119] 0 0
Gdansk
Country [120] 0 0
Poland
State/province [120] 0 0
Warszawa
Country [121] 0 0
Portugal
State/province [121] 0 0
Lisboa
Country [122] 0 0
Portugal
State/province [122] 0 0
Porto
Country [123] 0 0
Russian Federation
State/province [123] 0 0
Chelyabinsk
Country [124] 0 0
Russian Federation
State/province [124] 0 0
Moscow
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Nizhniy Novgorod
Country [126] 0 0
Russian Federation
State/province [126] 0 0
Omsk
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Samara
Country [128] 0 0
Russian Federation
State/province [128] 0 0
St Petersburg
Country [129] 0 0
Spain
State/province [129] 0 0
Andalucia
Country [130] 0 0
Spain
State/province [130] 0 0
Asturias
Country [131] 0 0
Spain
State/province [131] 0 0
Cadiz
Country [132] 0 0
Spain
State/province [132] 0 0
Catalunya
Country [133] 0 0
Spain
State/province [133] 0 0
Comunidad Valenciana
Country [134] 0 0
Spain
State/province [134] 0 0
Galicia
Country [135] 0 0
Spain
State/province [135] 0 0
Las Palmas de Gran Canaria
Country [136] 0 0
Spain
State/province [136] 0 0
Madrid
Country [137] 0 0
Sweden
State/province [137] 0 0
Goteborg
Country [138] 0 0
Sweden
State/province [138] 0 0
Lund
Country [139] 0 0
Sweden
State/province [139] 0 0
Stockholm
Country [140] 0 0
Switzerland
State/province [140] 0 0
Aargau
Country [141] 0 0
Switzerland
State/province [141] 0 0
Zuerich
Country [142] 0 0
Thailand
State/province [142] 0 0
Hat Yai
Country [143] 0 0
Thailand
State/province [143] 0 0
Bangkok
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Cornwall
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Surrey
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Leicester
Country [147] 0 0
United Kingdom
State/province [147] 0 0
London
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Manchester
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Middlesbrough
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Preston
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Rickmansworth Road

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT02967692